Get the Stockscreener App
0.7366
0.95%
0.0069
After Hours:
.73
-0.0066
-0.90%
Xilio Therapeutics Inc stock is traded at $0.7366, with a volume of 408.59K.
It is up +0.95% in the last 24 hours and up +5.23% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.7297
Open:
$0.73
24h Volume:
408.59K
Relative Volume:
0.73
Market Cap:
$38.18M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2489
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+5.26%
1M Performance:
+5.23%
6M Performance:
-10.72%
1Y Performance:
-10.17%
1-Day Range:
$0.7154
$0.7499
1-Week Range:
$0.6801
$0.80
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.7366 | 38.41M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Real time breakdown of Xilio Therapeutics Inc. stock performanceWeekly Profit Recap & AI Optimized Trade Strategies - Newser
Xilio Therapeutics Inc. stock retracement – recovery analysisQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
News impact scoring models applied to Xilio Therapeutics Inc.July 2025 Retail & Free AI Powered Buy and Sell Recommendations - Newser
Using portfolio simulators with Xilio Therapeutics Inc. includedEarnings Overview Summary & Community Consensus Picks - Newser
Trend analysis for Xilio Therapeutics Inc. this weekQuarterly Market Review & Real-Time Volume Trigger Notifications - Newser
Risk adjusted return profile for Xilio Therapeutics Inc. analyzedWeekly Trade Analysis & Technical Buy Zone Confirmations - Newser
Can you recover from losses in Xilio Therapeutics Inc.Portfolio Risk Summary & Low Risk Entry Point Tips - Newser
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued - MSN
What is the PEG ratio of Xilio Therapeutics Inc.Trade Exit Summary & Community Consensus Stock Picks - Lancaster City Council
Xilio initiates phase 2 trial for tumor-activated IL-12 therapy - Investing.com
Xilio starts phase 2 trial for XTX301, hits $17.5M milestone in Gilead license deal - MarketScreener
Xilio Therapeutics Announces Initiation of Phase 2 Trial - GlobeNewswire
Promising Cancer Drug Shows Partial Responses: Xilio's IL-12 Therapy Advances with $17.5M Gilead Backing - Stock Titan
Is Xilio Therapeutics Inc. impacted by rising ratesMarket Activity Recap & Daily Profit Focused Stock Screening - 뉴스영
Will Xilio Therapeutics Inc. benefit from rising consumer demand2025 Risk Factors & Momentum Based Trading Signals - beatles.ru
Will earnings trigger a reversal in Xilio Therapeutics Inc.Market Activity Report & Safe Investment Capital Preservation Plans - Newser
Is Xilio Therapeutics Inc. forming a double bottomJuly 2025 Reactions & Weekly High Potential Alerts - خودرو بانک
Should you hold or exit Xilio Therapeutics Inc. nowWeekly Stock Report & Momentum Based Trading Ideas - Newser
Using Bollinger Bands to evaluate Xilio Therapeutics Inc.Earnings Summary Report & Reliable Intraday Trade Alerts - Newser
What indicators show strength in Xilio Therapeutics Inc.Trade Performance Summary & Precise Swing Trade Alerts - Newser
Analyzing net buyer seller activity in Xilio Therapeutics Inc.Product Launch & Low Drawdown Momentum Trade Ideas - Newser
Institutional scanner results for Xilio Therapeutics Inc.2025 Geopolitical Influence & Detailed Earnings Play Alerts - Newser
How to read the order book for Xilio Therapeutics Inc.Take Profit & Capital Efficiency Focused Ideas - Newser
Xilio Therapeutics Faces Nasdaq Equity Compliance Challenge - MSN
Can Xilio Therapeutics Inc. deliver consistent dividendsMarket Activity Summary & Precise Trade Entry Recommendations - خودرو بانک
How institutional ownership impacts Xilio Therapeutics Inc. stockJuly 2025 Selloffs & Consistent Income Trade Ideas - Newser
Identifying reversal signals in Xilio Therapeutics Inc.Weekly Profit Report & Community Driven Trade Alerts - Newser
What drives Xilio Therapeutics Inc.’s stock priceJuly 2025 Review & Breakout Confirmation Trade Signals - خودرو بانک
Xilio Therapeutics Inc. stock daily chart insightsPortfolio Return Report & Low Risk High Reward Trade Ideas - Newser
Does Xilio Therapeutics Inc. have strong fundamentalsJuly 2025 Earnings & Short-Term Trading Opportunity Alerts - خودرو بانک
Insider Trends: Is Xilio Therapeutics Inc.’s ROE strong enough2025 Momentum Check & Fast Momentum Entry Tips - خودرو بانک
What’s the recovery path for long term holders of Xilio Therapeutics Inc.Earnings Beat & High Accuracy Swing Entry Alerts - Newser
What MACD and RSI say about Xilio Therapeutics Inc.Global Markets & Daily Price Action Insights - Newser
Developing predictive dashboards with Xilio Therapeutics Inc. data2025 Earnings Surprises & Entry Point Strategy Guides - Newser
Using RSI to spot recovery in Xilio Therapeutics Inc.Weekly Profit Summary & Safe Capital Investment Plans - Newser
Is Xilio Therapeutics Inc.’s ROE strong enoughWeekly Investment Recap & AI Forecast for Swing Trade Picks - خودرو بانک
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):